Astraea Therapeutics

Astraea Therapeutics is a privately-held, clinical-stage biotech founded in 2008 (not 2018 as in some records) and based in Mountain View, California. The company is advancing a pipeline of oral medicines targeting addiction to opioids, nicotine, and psychostimulants, with a core platform built on novel target validation in the neurobiology of relapse. Led by founder and CSO Dr. Nurulain Zaveri, Astraea's most advanced asset, AT-121, has demonstrated promising preclinical data for analgesia without addiction liability and is advancing into clinical development for smoking cessation. The company operates with a virtual or lean team model, leveraging external consultants for key development functions.

Platform centered on the neurobiology of relapse, targeting specific brain pathways genetically linked and clinically shown to be altered in addiction. Utilizes bifunctional small molecules, like dual NOP/MOR agonists, designed to separate therapeutic effects from adverse side effects.

Competes with established pharmacotherapies for addiction (e.g., buprenorphine, varenicline) and numerous companies developing new modalities for addiction and non-opioid pain. Differentiation hinges on Astraea's novel dual-receptor mechanism aiming to treat addiction and pain without abuse potential, a claim few competitors can make.